| Schedule of Accrued Liabilities |
Accrued expenses consisted of the following: | | | | | | | | | | | | September 30, 2018 | | December 31, 2017 | Compensation and benefits | | $ | — |
| | $ | 1,065,225 |
| Clinical costs | | 138,000 |
| | — |
| Other | | 91,401 |
| | 115,000 |
| Total | | $ | 229,401 |
| | $ | 1,180,225 |
|
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
The potentially dilutive securities, excluding out-of-the-money stock options and warrants, consisted of the following: | | | | | | | | | | | | | | | | Three Months Ended
September 30, | | Nine Months Ended
September 30, | | | 2018 | | 2017 | | 2018 | | 2017 | Options outstanding under the Private Innovate Plan | | 6,428,577 |
| | 6,509,824 |
| | 6,428,577 |
| | 6,509,824 |
| Options and warrants outstanding under the Amended Omnibus Plan (subject to stockholder approval) | | 1,202,843 |
| | — |
| | 1,202,843 |
| | — |
| Warrants issued at an exercise price of $2.54 | | 349,555 |
| | — |
| | 349,555 |
| | — |
| Warrants issued at an exercise price of $3.18 | | 1,410,309 |
| | — |
| | 1,410,309 |
| | — |
| Total | | 9,391,284 |
| | 6,509,824 |
| | 9,391,284 |
| | 6,509,824 |
|
|